CN103071020B - Externally applied ointment for treating child trachitis-bronchitis and pneumonia, and preparation method thereof - Google Patents
Externally applied ointment for treating child trachitis-bronchitis and pneumonia, and preparation method thereof Download PDFInfo
- Publication number
- CN103071020B CN103071020B CN201210584353.1A CN201210584353A CN103071020B CN 103071020 B CN103071020 B CN 103071020B CN 201210584353 A CN201210584353 A CN 201210584353A CN 103071020 B CN103071020 B CN 103071020B
- Authority
- CN
- China
- Prior art keywords
- external application
- bronchitis
- pneumonia
- weight
- application ointment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to an externally applied ointment for treating child trachitis-bronchitis and pneumonia, and a preparation method thereof. The externally applied ointment is prepared from the following traditional Chinese medicinal raw materials: pseudo-ginseng, paris polyphylla, polygonum cuspidatum, houttuynia cordata and liquorice; and auxiliary materials comprises glycerin monostearate, albolene, stearic acid, sodium laurylsulfate, glycerol, azone and nipagin ethyl ester oil. The externally applied ointment is prepared by performing ethanol extraction, water extraction, hot melting, heating and the like on the raw materials according to different characteristics of the raw materials and different parts by weight. The invention also particularly discloses the components of the externally applied ointment and the proportion of the components. The product is unique in formula and preparation and has obvious curative effect of treating child trachitis-bronchitis and pneumonia.
Description
Technical field
The invention belongs to medical technical field, external application ointment formulation and the processing technology thereof of specifically for children with tracheal-bronchitis, pneumonia, treating.
Background technology
World Health Organization (WHO) thinks that the large cause of death of department of pediatrics five is acute respiratory infection ARI, diarrhoea, measles, malaria and malnutrition.And ARI is that the five large causes of death are the first, wherein pneumonia is one of four large common diseases that threaten Chinese children health and lives, and its morbidity number, the number of dying of illness all occupy first of pediatric disease.Developing country infantile pneumonia pathogenetic bacteria mostly is virus, therefore in lower respiratory infection, use antibiotic maximum be pneumonia.
For tracheitis and bronchitis and pneumonia, pneumonia especially, take for many years always intravenous drip antibiotic and or antiviral drugs be main comprehensive treatment.Only have minority to add with treatment by Chinese herbs, antibiotic being widely used, especially irrational use, abuse, constantly increase Resistant strain, and the whole mankind's life and health in serious threat.The antibiotic of newly development upgrading is expensive, and the financial burden that has increased infants ' parents is also corresponding has restricted national economic development, and the increase of its side effect also exists potential danger.Venous transfusion itself just exists unsafe factor, and national medical treatment accident and the death toll occurring because of venous transfusion constantly increases, and infant also feels more painful because fearing venipuncture, and staying in the ward to look after the patient night and day, delaying work of the head of a family also makes it can't bear the heavy load.
In addition, in patent CN1299651A, the disclosed application for infantile bronchitis pneumonia is paste, clinical trial shows to exist following shortcoming: 1, when making owing to not passing through the extraction of the effective ingredient of medicine, actually be black plaster, after its coating, skin can not absorb very soon, and after coating, the incidence rate of local skin erythra has reached more than 47%; 2, due to this application directly contacts skin and apply after need to continue the long period, have obvious discomfort; 3, the healing fall flat to infantile bronchitis pneumonia, cure rate is low.
Summary of the invention
The present invention is directed to the problems referred to above, researched and developed a kind of external application ointment and method for making thereof for children with tracheal-bronchitis, pneumonia treatment, by the external application ointment formulation therapy of these research and development, obviously shortened the natural law of intravenous drip antibiotic or antiviral drugs, effectively alleviated the misery of infant and to refractory pneumonia better efficacy such as organizing pneumonias, the treatment of pneumonia acute stage has also been had to obvious curative effects.
Technical scheme of the present invention is: a kind of processing technology of the external application ointment for children with tracheal-bronchitis, pneumonia, and key is: this processing technology comprises the following steps:
(1) will effectively treat component gets the raw materials ready according to following ratio of weight and number:
Radix Notoginseng 55-65 part,
Rhizoma Paridis 25-35 part,
Rhizoma Polygoni Cuspidati 25-35 part,
Herba Houttuyniae 40-50 part,
Radix Glycyrrhizae 10-20 part;
(2) above-mentioned each component is pulverized respectively, is sieved:
(3) by Radix Notoginseng, Rhizoma Paridis soak with ethanol after pulverizing, sieving, separation soaking liquid, concentrated that liquid alcohol extract is standby;
(4) Rhizoma Polygoni Cuspidati after pulverizing, sieving, Herba Houttuyniae, Radix Glycyrrhizae water are decocted, isolated by filtration medicinal liquid, concentrated to obtain water extract stand-by;
(5) effective technique component is got the raw materials ready according to following ratio of weight and number:
Glyceryl monostearate 65-75 part,
White vaseline 80-90 part,
Stearic acid 110-115 part,
Sodium laurylsulfate 8-12 part,
Glycerol 80-90 part,
The 1-3% of the above weight summation of azone,
The 1-3 ‰ of the above weight summation of ethyl hydroxybenzoate,
(6) by above-mentioned vaseline, stearic acid, glyceryl monostearate, ethyl hydroxybenzoate mixing hot melt, and stir to oil phase, standby;
(7) sodium laurylsulfate, glycerol, azone are mixed, and add in step (3) in alcohol extract, with step (4) in water extract remix, be heated to water, standby;
(8) oil phase step (6) being obtained is added in water, stirs, and can make external application ointment after being cooled to room temperature;
(9) pack, dispatch from the factory.
Radix Notoginseng in step (3), Rhizoma Paridis soak with ethanol, carry out in two steps, soaks for the first time 1-3 hour, isolates raw material and add ethanol to soak for the second time, soaks 12-24 hour, after separation, alcohol extract concentrated standby.
Concentration of alcohol used is 60-70%.
In step (3), alcohol extract is concentrated, and being concentrated into proportion is that 1.1-1.3 is standby.
In step (4), the Rhizoma Polygoni Cuspidati after pulverizing, sieving, Herba Houttuyniae, the decoction of Radix Glycyrrhizae water, isolated by filtration medicinal liquid are carried out in two steps, the first step decocts with water 1-1.5 hour, isolate medicinal residues and decoct with water again 40-60 minute, filtering medicinal residues, concentrated after twice aqueous extract mixes.
After said aqueous extract mixes, concentrate and complete in concentration tank, the extracting solution proportion after concentrating reaches 1.1-1.3.
Pulverizing described in step (2), the operation of sieving are that Radix Notoginseng, Rhizoma Paridis, Rhizoma Polygoni Cuspidati, Herba Houttuyniae, Radix Glycyrrhizae powder are broken to 18-22 order.
A kind of external application ointment for children with tracheal-bronchitis, pneumonia treatment, according to formula Chinese herbal medicine components by weight percent than selecting materials, via extraction process obtain liquid active ingredients, with the medicine that oil phase adjuvant is mixed to form mutually, the components by weight percent of the raw material of Chinese medicine in this external application ointment comprises:
Radix Notoginseng 55-65 part,
Rhizoma Paridis 25-35 part,
Rhizoma Polygoni Cuspidati 25-35 part,
Herba Houttuyniae 40-50 part,
Radix Glycyrrhizae 10-20 part.
The components by weight percent of the oil phase adjuvant in this external application ointment comprises:
Glyceryl monostearate 65-75 part,
White vaseline 80-90 part,
Stearic acid 110-115 part,
Sodium laurylsulfate 8-12 part,
Glycerol 80-90 part,
The 1-3% of the above weight summation of azone,
The 1-3 ‰ of the above weight summation of ethyl hydroxybenzoate.
The invention has the beneficial effects as follows: this external application ointment is extracted, made after efficient concentration by effective ingredient, after coating and with gargalesthesia infant, obviously reduce, be only <1%, and other traditional pneumonia plasters when making owing to not passing through the extraction of the effective ingredient of medicine, actually be black plaster, after its coating, the incidence rate of local skin erythra has reached more than 47%.As can be seen here, at this external application ointment formulation aspect minimizing side effect, be far superior to other pneumonia plasters.Moreover this external application ointment is dosage form, be directly applied in use on skin, can be absorbed by the skin very soon, than traditional plaster, more easily by patient, accepted, be deeply subject to liking of infant and the head of a family.
Children's's body surface area is larger, and chest and back subcutaneous fat is less, and in this external application ointment, contained three kinds have the medicine of function of promoting blood circulation to disperse blood clots all to have short skin Absorption in various degree, then is share the object that azone can reach the quick absorption of promotion medicine and treatment completely.Within the scope of the ointment coating of this therapy, have 15 acupuncture points: 2, feishu cave, 2 of GAOGUANG acupoint, 1 of Body Pillar acupoint, HUATUOJIAJI acupoint breast 3-----breast 12 totally 10, effective to the treatment of pneumonia, tracheitis and bronchitis.Skin, to the in addition effect of medicine to these 15 acupuncture points of the absorption of medicine, is to kill two birds with one stone, and has amplified therapeutical effect.
Monarch drug is the medicine playing a major role in prescription, and ministerial drug is to assist monarch drug to reach the medicine of Main Function.Therefore except monarch drug, ministerial drug has also played the important function that is only second to monarch drug in prescription.By the research of patent CN1299651A and clinical trial are found, the ministerial drug forming in the component of disclosed application does not play good effect, causes the therapeutic effect of application low.We have added another taste ministerial drug-Rhizoma Polygoni Cuspidati by long term test in the external application ointment formulation for the treatment of children with tracheal-bronchitis, pneumonia, and this helper who increases is a very strong assistant.1), have a function of blood circulation promoting and blood stasis dispelling, relieving stagnation and freeing network vessels, anti-erythrocyte and antiplatelet aggregation the effect that has added three aspects: of Rhizoma Polygoni Cuspidati:, assist and strengthen monarch drug Radix Notoginseng improve the microcirculatory effect of lung, make lung microcirculation unobstructed, blood plasma oozes out minimizing, so just alleviated hypoxic-ischemic, alleviate pulmonary epithelial cells swelling and necrosis, alveolar structure is early recovered.On the other hand, the microcirculatory improvement of lung also makes the macrophage phagocytic digestion power in lung tissue strengthen, also can secrete a large amount of interferon and make natural killer cell--NK cytoactive strengthens with deactivation cause of disease, remove as early as possible cause of disease, degeneration necrosis tissue and exudate, repair lung pathological tissues early.In addition, complementing each other of Rhizoma Polygoni Cuspidati and monarch drug Radix Notoginseng, ministerial drug Rhizoma Paridis also can improve the immunity of organisms of infant except making the improvement of lung microcirculation, promotes the early recovery of pneumonia.2) there is antibacterial, antiviral effect, coordinate common disease-resistant formerly with Herba Houttuyniae, Radix Glycyrrhizae, make antibacterial, antivirus action in the treatment of infectious respiratory tract disease, apply more strong.3) Rhizoma Polygoni Cuspidati has antitussive, antiasthmatic effect, and with the cough with asthma of Rhizoma Paridis, Radix Glycyrrhizae co-therapy pneumonia, tracheitis, making antitussive, antiasthmatic effect is favourable for the treatment of respiratory system cough with asthma in fact.In a word, the adding of Rhizoma Polygoni Cuspidati, in treatment tracheitis and bronchitis, pneumonia, shown blood circulation promoting and blood stasis dispelling, improved lung microcirculation, larger superiority aspect antibacterial, antiviral, antitussive and antiasthmatic.
In the present invention's formula, ministerial drug is Rhizoma Paridis, Rhizoma Polygoni Cuspidati, and the two all has blood circulation promoting and blood stasis dispelling, and antiplatelet aggregation assists Radix Notoginseng to improve the microcirculatory effect of lung.In addition, Rhizoma Paridis still has heat-clearing and toxic substances removing, relieving cough and asthma, calmness and antibiosis and antiviral functions; That Rhizoma Polygoni Cuspidati still has is antibacterial, antiviral, antitussive and antiasthmatic function.Adjuvant drug is Herba Houttuyniae, has heat-clearing and toxic substances removing, and the heat of reducing phlegm disappear lung abscess and obvious antibacterial and antivirus action can strengthen leukocytes phagocytic ability and improve the function of immunity of organisms.To upper and lower respiratory tract infection, be widely used evident in efficacy.Making medicine is Radix Glycyrrhizae, and Chinese materia medica is decided to be Qi-tonifying drug, has the effect of the invigorating the heart and spleen deficiency of vital energy, still has the effect of adrenocortical hormone sample, has antiinflammatory, antiallergic, antiviral, protection Detoxication, the coordinating the actions of various ingredients in a prescription that the traditional Chinese medical science is conventional.It both can alleviate the inflammatory reaction of pulmonary, alleviated the permeability of the local wall of micrangium of lung, reduced blood plasma and oozed out, and alleviated the generation of the erythra that local skin stimulation is occurred.Azone is effectively short cutaneous permeable agent, can promote the effective ingredient of medicine to penetrate into fast in the interior lung tissue of body.Electromagnetic irradiation, make the telangiectasis in skin accelerate the quick absorption of medicine, drug for invigorating blood circulation and eliminating stasis itself also has this effect, at this external application ointment formulation, use anteroposterior diameter electromagnetic wave irradiation or pad towel to seal the absorption that hot skin rubefaction is more conducive to skin, also saved gauze simultaneously, use the convenient welcome that is more subject to infant and the head of a family thereof, be more better than traditional ointment plaster.
The specific embodiment
When concrete use, by following proportioning take raw material (gram):
Embodiment 1, Radix Notoginseng 62, Rhizoma Paridis 33, Rhizoma Polygoni Cuspidati 33, Herba Houttuyniae 47, Radix Glycyrrhizae 18 and effective technique adjuvant: glyceryl monostearate 72, white vaseline 87, stearic acid 114, sodium laurylsulfate 11, glycerol 87, azone, ethyl hydroxybenzoate, wherein, azone be above-mentioned effective technique adjuvant weight summation 1.5%, ethyl hydroxybenzoate is 1 ‰ of above-mentioned effective technique adjuvant weight summation.
Embodiment 2, Radix Notoginseng 55, Rhizoma Paridis 25, Rhizoma Polygoni Cuspidati 25, Herba Houttuyniae 40, Radix Glycyrrhizae 10 and effective technique adjuvant: glyceryl monostearate 65, white vaseline 80, stearic acid 110, sodium laurylsulfate 8, glycerol 80, azone, ethyl hydroxybenzoate, wherein, azone be above-mentioned effective technique adjuvant weight summation 1%, ethyl hydroxybenzoate is 1.5 ‰ of above-mentioned effective technique adjuvant weight summation.
Embodiment 3, Radix Notoginseng 60, Rhizoma Paridis 30, Rhizoma Polygoni Cuspidati 30, Herba Houttuyniae 45, Radix Glycyrrhizae 15 and effective technique adjuvant: glyceryl monostearate 70, white vaseline 85, stearic acid 112, sodium laurylsulfate 10, glycerol 85, azone, ethyl hydroxybenzoate, wherein, azone be above-mentioned effective technique adjuvant weight summation 2%, ethyl hydroxybenzoate is 2 ‰ of above-mentioned effective technique adjuvant weight summation.
Embodiment 4, Radix Notoginseng 65, Rhizoma Paridis 35, Rhizoma Polygoni Cuspidati 35, Herba Houttuyniae 50, Radix Glycyrrhizae 20 and effective technique adjuvant: glyceryl monostearate 75, white vaseline 90, stearic acid 115, sodium laurylsulfate 12, glycerol 90, azone, ethyl hydroxybenzoate, wherein, azone be above-mentioned effective technique adjuvant weight summation 3%, ethyl hydroxybenzoate is 3 ‰ of above-mentioned effective technique adjuvant weight summation.
Embodiment 5, Radix Notoginseng 58, Rhizoma Paridis 28, Rhizoma Polygoni Cuspidati 28, Herba Houttuyniae 43, Radix Glycyrrhizae 12 and effective technique adjuvant: glyceryl monostearate 68, white vaseline 83, stearic acid 111, sodium laurylsulfate 9, glycerol 83, azone, ethyl hydroxybenzoate, wherein, azone be above-mentioned effective technique adjuvant weight summation 1.2%, ethyl hydroxybenzoate is 1.2 ‰ of above-mentioned effective technique adjuvant weight summation.
Embodiment 6, Radix Notoginseng 63, Rhizoma Paridis 33, Rhizoma Polygoni Cuspidati 33, Herba Houttuyniae 47, Radix Glycyrrhizae 17 and effective technique adjuvant: glyceryl monostearate 73, white vaseline 88, stearic acid 114, sodium laurylsulfate 11, glycerol 87, azone, ethyl hydroxybenzoate, wherein, azone be above-mentioned effective technique adjuvant weight summation 2.8%, ethyl hydroxybenzoate is 2.8 ‰ of above-mentioned effective technique adjuvant weight summation.
A kind of processing technology of the external application ointment for children with tracheal-bronchitis, pneumonia treatment, step comprises: (1) first gets Radix Notoginseng, Rhizoma Paridis dry powder, adopting percolation concentration is 65% ethanol percolate extraction, carry out in two steps, soak for the first time 1-3 hour, isolate raw material and add ethanol to soak for the second time, soak 12-24 hour, after separation, alcohol extract alcohol extract is concentrated, and being concentrated into proportion is that 1.1-1.3 is standby; (2) get Rhizoma Polygoni Cuspidati, Herba Houttuyniae, Radix Glycyrrhizae, drying and crushing to 20 order fine powder, water decocts, isolated by filtration medicinal liquid carries out in two steps, the first step decocts with water 1-1.5 hour, isolate medicinal residues and decoct with water again 40-60 minute, filtering medicinal residues, are concentrated into proportion after twice aqueous extract mixes and are 1.1-1.3, standby; (3) get vaseline, stearic acid, glyceryl monostearate, ethyl hydroxybenzoate, by aforementioned four material hot melts and stir to oil phase, standby; (4) get sodium laurylsulfate, glycerol, azone, add above-mentioned alcohol extract, water extract to mix, be heated to water, standby; (5) oil phase step (3) being obtained is added in water, stirs, and can make preparation after being cooled to room temperature; (6) pack, dispatch from the factory, when packing, with moulding pipe or aluminum pipe, pack 10 grams every.In use, consumption: generally determine according to infant age size, general 5 years old following each with 1/2 bag, and 5 grams, 5 years old ~ 10 years old each with 2/3 bag, 10 years old above at every turn with 1 bag to be coated with very thin even one deck; Coating scope: by this ointment directly anterior axillary line, infant left and right with on for omoplate hilllock, left and right mid point (1/2 place) horizontal line being connected, be equivalent to the horizontal line of third dorsal vertebra, lower on the skin of back between twelfth rib bone horizontal line; Therapeutic Method and the course for the treatment of: before coating, with the skin of electromagnetic wave irradiation corresponding site 10 minutes, irradiation distance was moderate, with warm, notes occurring to irradiate scald; After coating, with electromagnetic wave, irradiate 5 minutes, now coating skin is worn the clothes with dry infant again.In family as without electromagnetic wave, after available heat towel wiping skin rubefaction, at coating, also can.
An important feature of the present invention is adding of Rhizoma Polygoni Cuspidati, complements each other with monarch drug Radix Notoginseng and ministerial drug Rhizoma Paridis, can assist and strengthen improving pulmonary circulation and having the effect of blood circulation promoting and blood stasis dispelling, relieving stagnation and freeing network vessels, anti-erythrocyte and antiplatelet aggregation of monarch drug Radix Notoginseng.Lung microcirculation is unobstructed, and blood plasma oozes out minimizing, has so just alleviated hypoxic-ischemic, alleviates pulmonary epithelial cells swelling and necrosis, and alveolar structure is early recovered.On the other hand, the microcirculatory improvement of lung also makes the macrophage phagocytic digestion power in lung tissue strengthen, and also can secrete a large amount of interferon and natural killer cell NK cytoactive is strengthened with deactivation cause of disease, removes as early as possible cause of disease, degeneration necrosis tissue and exudate, repair lung pathological tissues early.
Another one important feature of the present invention is the dosage form of this external application ointment, because this external application ointment formulation is extracted, made after efficient concentration by effective ingredient, after coating, skin can absorb very soon, in order to accelerate skin, absorb and can or pad the means acceleration skin absorption that towel be sealed hot skin with electromagnetic wave irradiation, after coating and with gargalesthesia infant, obviously reducing, is only <1%.And traditional pneumonia plaster when making owing to not passing through the extraction of the effective ingredient of medicine, be black plaster actually, after its coating, skin can not absorb very soon, after coating, the incidence rate of local skin erythra has reached more than 47%.
The result in clinical application of external application ointment formulation of the present invention shows to have following advantage:
1, the pure external application of Chinese medicine Ointment in Treatment of external application infantile pneumonia, especially evident in efficacy to refractory pneumonias such as delay property, the cure rate for the treatment of in 6 days reaches 93%;
2, the external application ointment that the present invention makes is nontoxic to human body, simple for use, and safe no pain in therapeutic process;
3, patient with slight symptoms can use separately, the mycoplasma pneumonia to light disease pneumonia and the outer symptom of some apneumias, and oral antibiotic or antiviral agents, external application ointment of the present invention, does not need venous transfusion to cure;
4, for patient with severe symptoms, venous transfusion and external application ointment of the present invention can be combined, but can greatly reduce the natural law of intravenous injection antibiotics, deeply be subject to infant and family members' thereof popular welcome, be the Gospel of pneumonia, tracheitis and bronchitis infant.
For showing that external application ointment of the present invention is to children with tracheal-bronchitis, the therapeutic effect of pneumonia, from being in hospital and internal clinic is selected 72 routine cases, wherein, case selection standard was: with Hu Yamei in 2002, the 7th edition fixed bronchopneumonia diagnostic criteria of Jiang Zaifang chief editor < < all good fortune halls practical paidonosology > > is standard, through conventional passages through which vital energy circulates antiinflammatory and symptomatic treatment more than 10 days and even have not yet fully recovered for 2 ~ 3 weeks, still have clinically cough in various degree, the symptom such as expectoration or asthma, auscultation of lung has the rale that more or less, and be difficult for disappearing, the two lung point lamellars of x line chest film inspection, streak shade absorbs not exclusively and all without congenital heart disease, pulmonary tuberculosis, myocarditis, malnutrition, rickets, anemia, respiratory system congenital diseases, immunodeficiency, the complication such as leukemia and tumor.Infant is divided into two groups at random.Test group 32 examples, male's 18 examples, women's 14 examples; Age 0-1 year 6 examples, 2 ~ 3 years old 20 example, 4 ~ 7 years old 6 example; Conventional vein antiinflammatory and 10 ~ 14 days symptomatic treatment time, 22 examples, 15 ~ 21 days 10 examples.Matched group 40 examples, male's 24 examples, women's 16 examples; Age 0-1 year 8 examples, 2 ~ 3 years old 28 example, 4 ~ 7 years old 4 example; Conventional vein antiinflammatory and 10 ~ 14 days symptomatic treatment time, 26 examples, 15 ~ 21 days 14 examples.
Therapeutic scheme:
Experimental group: 32 examples are inactive conventional vein antiinflammatory and symptomatic treatment all, makes external application ointment formulation treatment of the present invention with above-described embodiment 3.Matched group: 40 examples are inactive conventional vein antiinflammatory and symptomatic treatment all, with traditional pneumonia plaster treatment, wherein drug dosage and test group match, and drug of topical application every day once, continues 12 hours at every turn, within 6 days, is 1 course for the treatment of, treats altogether 6 days.
Curative effect judging standard:
Cure: treat the respiratory symptoms such as (6 days) cough 1 course for the treatment of, expectoration, dyspnea with rapid and short breath and disappear, the two pulmonary rales of chest auscultation disappear, and two pulmonary respiration sounds are normal, and the two lung point lamellar shades of x line chest film inspection disappear completely.
Effective: treat the most of disappearance of the respiratory symptoms such as (6 days) cough 1 course for the treatment of, expectoration, dyspnea with rapid and short breath, the two pulmonary rales of chest auscultation disappear substantially, but respiratory murmur still increases slightly.The two lung point lamellar shades of x line chest film inspection disappear substantially, but still have the streak shade that more or less.
Invalid: treat and still have the respiratory symptoms such as cough, expectoration, dyspnea with rapid and short breath 1 course for the treatment of (6 days), the two lungs of chest auscultation or a side lung still have the rale that more or less, and the two lungs of x line rabat or a side lung still have the some lamellar shade that more or less.
Clinical test results is as shown in table 1:
| Group | Cure (number of cases) | Effectively (number of cases) | Invalid (number of cases) |
| Experimental group | 30 | 1 | 1 |
| Matched group | 0 | 22 | 18 |
As can be seen from Table 1,32 children with bronchial pneumonia external application medicines of the present invention are done to therapeutic test, one 6 days courses for the treatment of cure rate up to 93.75%, substantially effectively account for 3.13%, invalid accounts for 3.13%, total effective rate is up to 96.88%.
Claims (9)
1. for a processing technology for the external application ointment of children with tracheal-bronchitis, pneumonia, it is characterized in that: processing technology comprises the following steps:
(1) will effectively treat component gets the raw materials ready according to following ratio of weight and number:
Radix Notoginseng 55-65 part,
Rhizoma Paridis 25-35 part,
Rhizoma Polygoni Cuspidati 25-35 part,
Herba Houttuyniae 40-50 part,
Radix Glycyrrhizae 10-20 part;
(2) above-mentioned each component is pulverized respectively, sieved;
(3) by Radix Notoginseng, Rhizoma Paridis soak with ethanol after pulverizing, sieving, separation soaking liquid, concentrated that liquid alcohol extract is standby;
(4) Rhizoma Polygoni Cuspidati after pulverizing, sieving, Herba Houttuyniae, Radix Glycyrrhizae water are decocted, isolated by filtration medicinal liquid, concentrated to obtain water extract stand-by;
(5) effective technique adjuvant is got the raw materials ready according to following ratio of weight and number:
Glyceryl monostearate 65-75 part,
White vaseline 80-90 part,
Stearic acid 110-115 part,
Sodium laurylsulfate 8-12 part,
Glycerol 80-90 part,
Azone and ethyl hydroxybenzoate; Wherein the parts by weight of azone are the 1-3% of above-mentioned 7 kinds of technique adjuvant weight summations, and the parts by weight of ethyl hydroxybenzoate are the 1-3 ‰ of above-mentioned 7 kinds of technique adjuvant weight summations,
(6) by above-mentioned white vaseline, stearic acid, glyceryl monostearate, ethyl hydroxybenzoate mixing hot melt, and stir to oil phase, standby;
(7) sodium laurylsulfate, glycerol, azone are mixed, and add the alcohol extract of step (3), the water extract of step (4) remixes, is heated to water, standby;
(8) oil phase step (6) being obtained is added in water, stirs, and can make external application ointment after being cooled to room temperature;
(9) pack, dispatch from the factory.
2. the processing technology of a kind of external application ointment for children with tracheal-bronchitis, pneumonia according to claim 1, it is characterized in that: the Radix Notoginseng in step (3), Rhizoma Paridis soak with ethanol, carry out in two steps, soak for the first time 1-3 hour, isolating raw material adds ethanol to soak for the second time, soak 12-24 hour, after separation, soak is concentrated standby.
3. the processing technology of a kind of external application ointment for children with tracheal-bronchitis, pneumonia according to claim 2, is characterized in that: concentration of alcohol used is 60-70%.
4. the processing technology of a kind of external application ointment for children with tracheal-bronchitis, pneumonia according to claim 1, is characterized in that: concentrated described in step (3), be to be concentrated into proportion 1.1-1.3.
5. the processing technology of a kind of external application ointment for children with tracheal-bronchitis, pneumonia according to claim 1, it is characterized in that: in step (4), the Rhizoma Polygoni Cuspidati after pulverizing, sieving, Herba Houttuyniae, the decoction of Radix Glycyrrhizae water, isolated by filtration medicinal liquid are carried out in two steps, the first step decocts with water 1-1.5 hour, isolate medicinal residues and decoct with water again 40-60 minute, filtering medicinal residues, concentrated after twice medicinal liquid mixes.
6. the processing technology of a kind of external application ointment for children with tracheal-bronchitis, pneumonia according to claim 5, is characterized in that: after described medicinal liquid mixes, concentrate and complete in concentration tank, the proportion after concentrating reaches 1.1-1.3.
7. the processing technology of a kind of external application ointment for children with tracheal-bronchitis, pneumonia according to claim 1, is characterized in that: the pulverizing described in step (2), the operation of sieving are that Radix Notoginseng, Rhizoma Paridis, Rhizoma Polygoni Cuspidati, Herba Houttuyniae, Radix Glycyrrhizae powder are broken to 18-22 order.
8. the external application ointment for the treatment of children with tracheal-bronchitis, pneumonia, described external application ointment for selecting materials according to herbal raw material ratio of weight and number, via extraction process obtain liquid active ingredients, with the medicine that effective technique adjuvant is mixed to form mutually, it is characterized in that: the ratio of weight and number of the herbal raw material in this external application ointment is:
Radix Notoginseng 55-65 part,
Rhizoma Paridis 25-35 part,
Rhizoma Polygoni Cuspidati 25-35 part,
Herba Houttuyniae 40-50 part,
Radix Glycyrrhizae 10-20 part.
9. the external application ointment for the treatment of children with tracheal-bronchitis, pneumonia according to claim 8, is characterized in that: the effective technique adjuvant in this external application ointment consists of following weight component:
Glyceryl monostearate 65-75 part,
White vaseline 80-90 part,
Stearic acid 110-115 part,
Sodium laurylsulfate 8-12 part,
Glycerol 80-90 part,
Azone and ethyl hydroxybenzoate; Wherein the parts by weight of azone are the 1-3% of above-mentioned 7 kinds of technique adjuvant weight summations, and the parts by weight of ethyl hydroxybenzoate are the 1-3 ‰ of above-mentioned 7 kinds of technique adjuvant weight summations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210584353.1A CN103071020B (en) | 2012-12-30 | 2012-12-30 | Externally applied ointment for treating child trachitis-bronchitis and pneumonia, and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210584353.1A CN103071020B (en) | 2012-12-30 | 2012-12-30 | Externally applied ointment for treating child trachitis-bronchitis and pneumonia, and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103071020A CN103071020A (en) | 2013-05-01 |
| CN103071020B true CN103071020B (en) | 2014-08-20 |
Family
ID=48147865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210584353.1A Active CN103071020B (en) | 2012-12-30 | 2012-12-30 | Externally applied ointment for treating child trachitis-bronchitis and pneumonia, and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103071020B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102134046B1 (en) * | 2012-06-05 | 2020-07-14 | 오라텍 세라퓨틱스 엘엘씨 | Pharmaceutical composition for treating inflammation and pain |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1299651A (en) * | 2000-02-03 | 2001-06-20 | 天津中医学院第二附属医院 | Dressing for treating infantile bronchitis and pulmonitis and its preparation |
| CN1451433A (en) * | 2003-05-07 | 2003-10-29 | 赤峰万泽制药有限责任公司 | Shenji ointment and preparing process thereof |
| CN1631369A (en) * | 2003-12-23 | 2005-06-29 | 高克 | Cream for treating skin disease |
| CN101507798A (en) * | 2009-03-24 | 2009-08-19 | 宋英杰 | Traditional Chinese medicine capable of chronic bronchitis and pulmonary heart disease |
-
2012
- 2012-12-30 CN CN201210584353.1A patent/CN103071020B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1299651A (en) * | 2000-02-03 | 2001-06-20 | 天津中医学院第二附属医院 | Dressing for treating infantile bronchitis and pulmonitis and its preparation |
| CN1451433A (en) * | 2003-05-07 | 2003-10-29 | 赤峰万泽制药有限责任公司 | Shenji ointment and preparing process thereof |
| CN1631369A (en) * | 2003-12-23 | 2005-06-29 | 高克 | Cream for treating skin disease |
| CN101507798A (en) * | 2009-03-24 | 2009-08-19 | 宋英杰 | Traditional Chinese medicine capable of chronic bronchitis and pulmonary heart disease |
Non-Patent Citations (2)
| Title |
|---|
| 张淑芬等.抗白灵霜治疗局限型白癜风31例.《南京中医药大学学报》.1997,第13卷(第3期), |
| 抗白灵霜治疗局限型白癜风31例;张淑芬等;《南京中医药大学学报》;19971231;第13卷(第3期);184 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103071020A (en) | 2013-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101081291A (en) | Medicine for treating cancer | |
| CN107308419A (en) | A kind of Traditional Chinese medicine for steeping foot powder for treating stomach cold crymodynia | |
| US10953062B2 (en) | Anticancer pharmaceutical composition and application thereof | |
| CN103071020B (en) | Externally applied ointment for treating child trachitis-bronchitis and pneumonia, and preparation method thereof | |
| CN104784245A (en) | Medicine for treating cervical cancer | |
| CN103656048A (en) | Drug for treating cow mastitis and preparation method thereof | |
| CN112675280A (en) | Composition for preventing and treating carsickness and preparation method thereof | |
| CN106729498A (en) | A kind of albumen powder eaten after chemicotherapy and preparation method thereof | |
| CN105343344A (en) | Yin and lung nourishing formula for treating silicosis and preparation method | |
| CN105106634A (en) | Traditional Chinese medicine preparation for treating acute appendicitis and application thereof | |
| CN107335034A (en) | A kind of external medicine composition for treating leucoderma and its application | |
| CN102552619B (en) | Medicine for treating tumor and preparation method thereof | |
| CN101721610B (en) | Medicine for treating tumors | |
| CN106728618A (en) | A kind of Chinese medicine for treating Severe Acute Pancreatitis SAP | |
| CN106729011A (en) | A kind of topical composition | |
| CN105267939A (en) | Traditional Chinese medicine composition for treating superficial phlebitis | |
| CN105106712A (en) | Nutritional porridge capable of helping postoperative recovery of cancer patient and preparation method thereof | |
| CN104840793A (en) | Pure traditional Chinese medicine cooling gel sheet for high fever of kids and method for preparing same | |
| CN112245551A (en) | Pure traditional Chinese medicine transdermal liniment for treating liver diseases and preparation method thereof | |
| CN105031389A (en) | Traditional Chinese medicine tablet for restraining malignant tumor breeding in cooperation with radiotherapy and preparing method of traditional Chinese medicine tablet | |
| CN104784587A (en) | Traditional Chinese medicine composition for treating endocrine disorder type infertility and preparation method thereof | |
| CN104740487B (en) | A kind of Chinese medicine composition for treating children anorexia and preparation method thereof | |
| CN114010755A (en) | Preparation for controlling uric acid and preparation method thereof | |
| CN111494557A (en) | Plant enzyme traditional Chinese medicine wine and preparation method thereof | |
| CN104435525A (en) | Traditional Chinese medicine composition for preventing and treating bacterial endocarditis and preparation method of traditional Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |